Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

  title={Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent},
  author={Keith Pettengell and J H Mynhardt and T McD Kluyts and Wendi M Lau and David P. Facklam and Donald N. Buell},
  journal={Alimentary Pharmacology \& Therapeutics},
Aim : To determine the minimum effective dose and safety of micafungin in the treatment of HIV‐related oesophageal candidiasis. 

A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis

The objective of this study is to determine efficacy and safety of intravenous micafungin vs. intravenous fluconazole in the treatment of oesophageal candidiasis.

Developments in the treatment of candidiasis: more choices and new challenges

Systemic antifungal therapy can now be individualised based on the severity of the infection, comorbid conditions and the Candida spp.

Micafungin: an evidence-based review of its place in therapy

The first marketed echinocandin, micafungin, was approved in 2005 for the treatment of esophageal candidiasis and prophylaxis of invasive Candida infections in patients undergoing hematopoietic stem cell transplantation and has a favorable tolerability profile with no significant drug interactions and does not need adjustment for renal or hepatic insufficiency.

Micafungin: the US perspective

Micafungin holds promise as a first-line treatment option for candidiasis, as well as prophylaxis against invasive fungal infections during periods of neutropenia in high-risk patients.

[Scientific evidence supporting the use of micafungin in the treatment of invasive candidiasis].

Pharmacotherapy of Micafungin: Clinical Review

Micafungin, an echinocandin that inhibits the synthesis of 1,3-b-D glucan, an essential cell wall component of Candida species, has a very favorable safety profile with few adverse events and minimal drug-drug interactions.

Micafungin for candidiasis

The results from the largest studies of micafungin among patients with invasive and esophageal candidiasis are reviewed, and the use of echinocandins in this increasingly common disorder is supported.

Review of the pharmacology and clinical studies of micafungin

It is administered intravenously as a once daily infusion and does not require dose adjustments for renal or moderate hepatic dysfunction, and its safety record, favorable tolerability profile, and few drug interactions make it an important agent for the treatment of invasive fungal infections.

Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.

Micafungin is a valuable first-line or alternative option to other antifungal agents for the management of candidaemia and invasive candidiasis in adult and paediatric patients, including neonates, and as prophylaxis against fungal infections in patients undergoing HSCT.

Early Clinical Experience with Anidulafungin at a Large Tertiary Care Medical Center

It is suggested that early clinical experience with anidulafungin should be considered as an indication for further study to determine if it is safe and effective to treat central giant cell granuloma.



Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases.

  • T. WalshJ. Hiemenz E. Anaissie
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
Findings support the use of ABLC in the treatment of invasive fungal infections in patients who are intolerant of or refractory to conventional antifungal therapy.

New drugs and novel targets for treatment of invasive fungal infections in patients with cancer.

New antifungal compounds are being developed, which may improve the therapeutic armamentarium for prevention and treatment of invasive mycoses in high-risk patients with neoplastic diseases.

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis.

Caspofungin appeared to be as effective as and better tolerated than amphotericin B for the treatment of esophageal candidiasis and provides the first demonstration of clinical utility for an echinocandin compound.

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.

Results from pre-clinical evaluations performed to date indicate that FK463 should be a potent parenteral antifungal agent.

Antifungal agents: chemotherapeutic targets and immunologic strategies

This minireview briefly discusses the antifungal agents currently in clinical use, and considers the use of promising new biochemical targets in fungi as well as host-based, immunological approaches as evolving strategies for antIFungal therapy.

Oropharyngeal and esophageal candidiasis in immunocompromised patients: treatment issues.

  • R. Darouiche
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 1998
Oropharyngeal candidiasis is the most common opportunistic infection in patients with HIV infection, occurring in as many as 90% of HIV-positive patients at some point during the course of HIV disease.

Comparative Antifungal Activities and Plasma Pharmacokinetics of Micafungin (FK463) against Disseminated Candidiasis and Invasive Pulmonary Aspergillosis in Persistently Neutropenic Rabbits

Micafungin demonstrated concentration-dependent and dosage-dependent clearance of C. albicans and A. fumigatus from persistently neutropenic rabbits with invasive pulmonary aspergillosis and in vivo findings correlated with the results of in vitro time-kill assays that demonstrated that micafungins has concentration- dependent fungicidal activity.

Practice Guidelines for the Treatment of Candidiasis

This document summarizes current knowledge about treatment of multiple forms of candidiasis and is the guideline of the Infectious Diseases Society of America for the treatment ofCandida, covering 4 major topical areas.

Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

Although no established interpretative breakpoints are available for the candins (CFG, MFG, and AFG) and the new azoles (VOR and POS), they all exhibited excellent antifungal activity, even for those strains resistant to the other aforementioned agents.

Efficacy of FK463, a New Lipopeptide Antifungal Agent, in Mouse Models of Disseminated Candidiasis and Aspergillosis

Results indicate that FK463 may be a potent parenterally administered therapeutic agent for disseminated candidiasis and aspergillosis.